A CDKN2A (p16) Mutation AssociatedWith Familial Pancreatic Cancer Reduces Protein Stability and Functionality

被引：0
|
作者：
Horn, I. P. [1 ]
Marks, D. L. [1 ]
Hogenson, T. L. [1 ]
Almada, L. L. [1 ]
Goldstein, L. E. [1 ]
Duran, P. A. Romecin [1 ]
Vrabel, A. M. [1 ]
Cui, G. [2 ]
Chaffee, K. G. [3 ]
Bamlet, W. R. [3 ]
Mer, G. [2 ]
Li, H. [4 ]
Petersen, G. M. [5 ]
Fernandez-Zapico, M. E. [1 ]
机构：
[1] Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Rochester, MN USA
[2] Mayo Clin, Div Biochem & Mol Biol, Rochester, MN USA
[3] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA
[4] Mayo Clin, Div Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[5] Mayo Clin, Div Epidemiol, Rochester, MN USA
来源：
PANCREAS | 2018年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1393 / 1394
页数：2
相关论文
共 50 条
  • [21] Transcriptional regulation of CDKN2A/p16 by sirtuin 7 in senescence
    Rodriguez, Sergio
    Bermudez, Litzy
    Gonzalez, Daniel
    Bernal, Camila
    Canas, Alejandra
    Henriquez, Berta
    Rojas, Adriana
    Morales-Ruiz, Teresa
    MOLECULAR MEDICINE REPORTS, 2022, 26 (05)
  • [22] Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas
    Dacic, S.
    Popper, H. H.
    Kothmaier, H.
    Halbwedl, I.
    Morbini, P.
    Murer, B.
    Comin, C. E.
    Galateau-Salle, F.
    Demirag, F.
    Zeren, H.
    Attanoos, R.
    Gibbs, A.
    Cagle, P. T.
    LABORATORY INVESTIGATION, 2008, 88 : 339A - 340A
  • [23] CDKN2A/p16 is inactivated in most melanoma cell lines
    Castellano, M
    Pollock, PM
    Walters, MK
    Sparrow, LE
    Down, LM
    Gabrielli, BG
    Parsons, PG
    Hayward, NK
    CANCER RESEARCH, 1997, 57 (21) : 4868 - 4875
  • [24] Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-Leiden)
    Cappel, WHDTN
    Offerhaus, GJA
    van Puijenbroek, M
    Caspers, E
    Gruis, NA
    de Snoo, FA
    Lamers, CBHW
    Griffioen, G
    Bergman, W
    Vasen, HFA
    Morreau, H
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3598 - 3605
  • [25] Evaluation of p16 Protein Expression and CDKN2A Deletion in Conventional and Fibrosarcomatous Dermatofibrosarcoma Protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie
    Shon, Wonwoo
    LABORATORY INVESTIGATION, 2017, 97 : 136A - 136A
  • [26] Evaluation of p16 Protein Expression and CDKN2A Deletion in Conventional and Fibrosarcomatous Dermatofibrosarcoma Protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie
    Shon, Wonwoo
    MODERN PATHOLOGY, 2017, 30 : 136A - 136A
  • [27] Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas
    Dacic, S.
    Poppei, H. H.
    Kothmaier, H.
    Halbwedt, I.
    Morbini, P.
    Murer, B.
    Comin, C. E.
    Galateau-Salle, F.
    Demirag, F.
    Zeren, H.
    Allanoos, R.
    Gibbs, A.
    Cagle, P. T.
    MODERN PATHOLOGY, 2008, 21 : 339A - 340A
  • [28] HOMOZYGOTES FOR CDKN2 (P16) GERMLINE MUTATION IN DUTCH FAMILIAL MELANOMA KINDREDS
    GRUIS, NA
    VANDERVELDEN, PA
    SANDKUIJL, LA
    PRINS, DE
    WEAVERFELDHAUS, J
    KAMB, A
    BERGMAN, W
    FRANTS, RR
    NATURE GENETICS, 1995, 10 (03) : 351 - 353
  • [29] Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie L.
    Shon, Wonwoo
    PATHOLOGY, 2018, 50 (04) : 474 - 475
  • [30] UVB-induced decrease of p16/CDKN2A expression in skin cancer patients
    Krähn, G
    Leiter, U
    Udart, M
    Kaskel, P
    Peter, RU
    PIGMENT CELL RESEARCH, 2001, 14 (03): : 201 - 205
12345